-
Odanacatib (INN;
codenamed MK-0822) is an
investigational treatment for
osteoporosis and bone metastasis. It is an
inhibitor of
cathepsin K, an enzyme...
- of
mouse cathepsin K
structural elements that
regulate the
potency of
odanacatib". The
Biochemical Journal. 474 (5): 851–864. doi:10.1042/BCJ20160985....
- (INN)
Ocuclear Ocufen Ocuflox O****ycin
Ocupress Ocusert Pilo
Ocusulf odanacatib (USAN)
odronextamab (INN)
odulimomab (INN)
ofatumumab (INN)
Ogestrel Ogivri...
- and
chronic pain.
Cathepsin K inhibitors, Relacatib, Balicatib, and
Odanacatib, were
terminated during clinical trials at
phases I, II, and III, respectively...
- inhibitor,
odanacatib, in
Phase III
clinical trials for osteoporosis. In September, 2016,
Merck announced they were
discontinuing development of
odanacatib after...
-
actually used in
other pharmaceutical applications for the
production of
Odanacatib, and Sofosbuvir. Zau****syna O,
Berillo D,
Kirsebom H, Matti****on B (2013)...
